Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine

Leuk Lymphoma. 2016 Sep;57(9):2204-7. doi: 10.3109/10428194.2015.1126589. Epub 2015 Dec 24.

Affiliations

¹ a Department of Hematology , Tokyo Women's Medical University , Tokyo , Japan ;
² b Division of Hematology, Department of Internal Medicine , Nippon Medical School , Tokyo , Japan ;
³ c Department of Hematology/Oncology , Tokyo Women's Medical University Yachiyo Medical Center , Chiba , Japan ;
⁴ d Department of Health Science , Daito Bunka University , Tokyo , Japan.

PMID: 26699798
DOI: 10.3109/10428194.2015.1126589

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Bendamustine Hydrochloride / therapeutic use*
CD4-CD8 Ratio
Cytomegalovirus / drug effects
Cytomegalovirus / physiology*
Humans
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / immunology
Lymphoma, B-Cell / pathology
Lymphoma, B-Cell / virology*
Neoplasm Grading
Remission Induction
Risk Factors
Virus Activation / drug effects
Virus Activation / physiology*

Substances

Bendamustine Hydrochloride